NewLimit, a longevity company co-founded by Coinbase chief executive Brian Armstrong, has raised $435 million to push its first drug toward a test in people1. The round was led by the venture firm Founders Fund and valued the company at $3.1 billion2. NewLimit plans its first human trial in 2027, in alcohol-related liver disease3.
The round was first announced in early June1, and it drew fresh attention this month in coverage of tech founders moving into aging science2. This is Biohack’s first article following NewLimit. It is a funding story: no human results exist yet.
What happened
BioPharma Dive called the $435 million “Series C” (a company’s third major funding round) one of the largest so far this year for a biotechnology firm1. Besides Founders Fund, the round included Thrive Capital, Greenoaks, Quiet Capital and Eli Lilly Ventures, the investment arm of the drugmaker, among others1.
The new valuation is about three times what the company was worth a year earlier, according to a company profile compiled by Silicon Valley Investclub4. In May 2025 NewLimit raised $130 million in a round led by Kleiner Perkins at an $810 million valuation, and in October 2025 it added $45 million at a $1.6 billion valuation, when Eli Lilly joined as an investor45. Before that it raised $40 million in its first big round5.
Reports differ on the total. Endpoints News lists $682 million raised6. The Silicon Valley Investclub profile gives $682 million in one place, but $750 million and $782 million elsewhere on the same page4.
What the company is trying to do
NewLimit works on what scientists call “epigenetic reprogramming”1. Every cell carries the same DNA, but chemical markers on top of it tell each cell which genes to switch on or off. Those patterns wear away with age, and cells start to lose track of their jobs5. The company’s aim is to reset those patterns to a younger state5.
The idea builds on Nobel Prize-winning work by Shinya Yamanaka, who found that four proteins can turn adult cells back into embryo-like stem cells5. Turning cells all the way back carries risks, including tumors5. NewLimit says it is aiming for a partial reset: restoring how a cell works without reverting it to a stem cell4.
To find the right protein combinations, the company uses single-cell measurements, machine learning and large-scale lab screening in a repeating loop, where computer models suggest candidates, experiments test them, and the results retrain the models5. The profile says NewLimit’s own AI model for this is called Ambrosia, and that the drug is delivered in lipid nanoparticles, the tiny fat bubbles used in mRNA COVID vaccines4.
The evidence so far
All of NewLimit’s reported results come from cells in lab dishes and from animals5. As described by Excedr, the company has prototype medicines in three areas5:
- Liver: three protein combinations that, the company reports, restore aged liver cells’ ability to process fat and alcohol, and that showed effects in animal models of liver disease5.
- Immune system: three combinations that restored more youthful function to aged T cells, a type of immune cell, in lab studies5.
- Blood vessels: a newer program aimed at the cells that line blood vessels5.
Announcing the round, Armstrong made a broad claim, quoted in the company profile4:
NewLimit now has a prototype drug that reverses the age of some human cells.
That statement refers to cells, not people. The liver program is the one headed for the clinic. BioPharma Dive reported the company described it as a liver reprogramming therapy, with the first clinical trial to start in 20271. The profile says the company plans to file for that first trial in 20274.
What it does not show yet
Money is not evidence. None of NewLimit’s results have been tested in a human trial, and the findings described so far are company-reported preclinical work, meaning research done before any testing in people5. It is not known yet whether the liver drug is safe in humans, whether it helps people with liver disease, or whether any effect lasts.
There is also a gap between the company’s long-range goal and its first test. NewLimit says its mission is to add healthy years to human life4. But no therapy aimed at aging itself has ever been approved by the FDA, partly because aging is not recognized as a disease5. So the first trial targets one named disease, and success there would not on its own show anything about slowing aging in general.
Who is behind it
NewLimit was founded in 2021 by Armstrong, former GV (Google Ventures) partner Blake Byers and computational biologist Jacob Kimmel, who previously worked at Calico, the aging company backed by Alphabet4. Kimmel is the company’s CEO; the company is based in South San Francisco6.
Armstrong has called reversing cellular aging “the most important problem I could be working on after crypto”2. He was also listed as an individual investor in the company’s 2025 round4. Eli Lilly, one of the world’s largest drugmakers, has invested in both the 2025 extension and the latest round4.
Observers have focused on NewLimit’s choice of route. A healthcare newsletter argued that the company picked the most conventional path in drug development: aim a cell mechanism at a named disease and take it through the FDA’s standard application to start human testing3. It contrasted that with paid wellness services that sell biological-age dashboards and unapproved peptides3.
How it fits the field
NewLimit is one of several aging companies backed by tech money. OpenAI’s Sam Altman put $180 million into Retro Biosciences, and Jeff Bezos backed Altos Labs, which TradeFlock says leads the field at $5.56 billion in total funding2. The Silicon Valley Investclub profile lists Retro, Altos and Calico as NewLimit’s competitors4.
Not every outsider-founded longevity startup has done well. TradeFlock pointed to a Forbes analysis by healthcare analyst Sindhya Valloppillil, who described how many venture-backed longevity startups failed, with founders from tech and consumer brands lacking “operational depth” in areas like clinical compliance and treatment quality2. TradeFlock also noted that money flowing to a few well-known names does not mean money is flowing to the whole field2.
What to watch next
- Whether NewLimit files with the FDA and starts its liver trial in 2027, as planned4.
- Whether the company publishes its lab and animal data so outside scientists can check it.
- Progress on the immune and blood vessel programs, which so far rest on lab work5.
- Any safety findings, given the known tumor risk of full reprogramming5.
For now, the news is that investors are betting heavily on the idea. Whether the drug does anything in people is a question the planned trial is meant to start answering.
